Under the terms of the agreement, the Company and the University of Leipzig will have 12 months to negotiate a definitive license agreement, and the Company will work
The 12-month option provides an additional $2.1 million to Soligenix to advance OrbeShield as a medical countermeasure (MCM) for the treatment of gastrointestinal acute radiation syndrome (GI ARS).
"The initiation of this human abuse liability study is a key milestone in the development path for CR845," said Robert Medve, M.D., Chief Medical Officer of Cara Therapeutics.
ChromaDex will provide Murdoch Childrens Research Institute with quantities of its proprietary NIAGEN™ nicotinamide riboside (NR) ingredient for research use. ChromaDex’s NIAGEN is the first and only commercially
Today’s approval follows the positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in June 2014. KALYDECO was first approved in Europe in July 2012
Developing improved biologically active molecules has benefited from the use of substituents that are chemically stable, resistant to metabolism, and combine lipophilicity with polarity to improve binding and
The interim analysis demonstrated that treatment with ofatumumab (Arzerra) met the primary endpoint of improving progression free survival (PFS). The study evaluated ofatumumab maintenance therapy versus no further
The patent covers Full COLD-PCR, a foundation for the company’s highly sensitive ICE COLD-PCR technology. The COLD-PCR technology is owned by the Dana-Farber Cancer Institute, Boston USA, and
These broadly neutralizing antibodies (bNAbs) were discovered in collaboration with the International AIDS Vaccine Initiative (IAVI) and The Scripps Research Institute using Theraclone’s proprietary I-STAR technology. The I-STAR
This open-label trial will enroll 10-15 patients who will receive two bertilimumab infusions, at a dose of 10 mg/kg, on days 0 and 14. Patients will also start
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.